Loading clinical trials...
Loading clinical trials...
This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Allergan
NCT03135327 · Multiple Sclerosis, Dry Eye Syndromes, and more
NCT02585414 · Dry Eye Syndromes
NCT06848829 · Dry Eye Syndromes
NCT06220474 · Dry Eye Syndromes, Meibomian Gland Dysfunction
NCT06291194 · Dry Eye Syndromes
Sall Research Medical Center
Artesia, California
Lugene Eye Institute
Glendale, California
Lakeside Vision Center
Irvine, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions